免疫治疗和靶向药物对癌症患者的性腺毒性及其对后续妊娠的影响
本文综述免疫治疗和新型靶向药物对癌症患者性腺毒性的最新证据,涵盖作用机制、临床前与临床数据及其对后续妊娠机会和风险的影响,旨在为医生和患者在生育力保存及家庭规划决策中提供参考。
要点
- 传统细胞毒性药物对生育力的影响已明确,新型免疫和靶向治疗的性腺毒性尚待阐明。
- 临床证据有限,但临床前雌雄动物模型显示多种新疗法可能影响生殖能力。
- 这些治疗对患者生殖潜能的可能影响亟待解决,以指导生育力保存和家庭规划。
核心结论
- 免疫治疗和靶向药物对性腺毒性的临床证据有限,但临床前动物模型显示多种新疗法可能影响生殖能力,其影响亟待解决。
研究设计与样本
- 本文为综述,旨在汇总免疫治疗和新型靶向药物性腺毒性的最新证据,涵盖作用机制、临床前和临床可用数据及对后续妊娠的影响。
主要发现
- 传统细胞毒性药物对癌症患者生育力和生殖健康的作用已明确。
- 新型治疗对生育力和生殖健康的影响仍是未满足的医疗需求。
- 临床前雌性和雄性动物模型中,若干新疗法显示可能影响生殖能力。
临床怎么用
- 本文旨在为医生和患者提供工具,以便在接触新型抗癌治疗前后就生育力保存和家庭规划做出知情决策。
局限性
- 目前关于靶向药物和免疫治疗潜在性腺毒性的临床证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, cancer treatment has been revolutionized by the introduction of many novel drugs, including immunotherapy and targeted agents, which have significantly improved the prognosis of patients with different solid tumors. While the role of traditional cytotoxic agents on fertility and reproductive health of patients with cancer is currently well established, the impact of novel treatments remains an unmet medical need and a subject of concern. Limited clinical evidence exists to date on the potential gonadotoxicity of targeted agents and immunotherapy. However, in preclinical male and female animal models, several new treatments have demonstrated the potential to affect reproductive capacity. Hence, the possible impact of these treatments on patients' reproductive potential should be urgently addressed. This work aims to review the most recent evidence regarding the gonadotoxicity of immunotherapy and novel targeted agents from the mechanisms of action of these treatments to the preclinical and clinical available data, as well as the implications on chances and risks of subsequent pregnancies. The final aim is to provide a useful tool to both physicians and patients for an informed decision-making process regarding fertility preservation and family planning before and after exposure to the new anticancer treatments.
引用
- Arecco L, de Moura Leite L, Gentile G, et al. Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies. Hum Reprod. 2025. PMID: 40482082. doi:10.1093/humrep/deaf096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。